ESMO Annual Meeting
October 17 – 21, 2025 | Berlin, Germany

As part of scientific exchange, Novartis is providing the most recent abstract(s) and/or presentation(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Before prescribing any product, always refer to the Prescribing Information (PI), Summary of Product Characteristics (SmPC), or product information as appropriate in your country. Information is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Not all content may be available. Dependent on congress policy, links to the original poster/slide deck may only be available via the congress site where registration may be needed to access. This is for your background and educational purposes only and may not be altered or further disseminated in any fashion.
For distribution in response to an unsolicited request for medical information subject to local approval.

Content to be used in accordance with local CPO guidelines

List of Presentations

Final Analysis of Open-label Single-arm Study on Dabrafenib + Trametinib in Chinese Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer

Jianya Zhou, Yan Yu, Yun Fan, Jialei Wang, Juan Li, Jun Zhao, Yongchang Zhang, Nong Yang, Zhehai Wang, Tong Zhu, Marina Miskic, Haifu Li, Li Gao, Li Zhang

  • Poster Presentation #2004P
    Hall 25 | Saturday, October 18, 2025 | 09:00-17:00 CEST (Poster)

This presentation will be available once the congress embargo lifts
View list of select presentations for this compound